Suppr超能文献

探索欧洲结核病病例治疗成功的决定因素。

Exploring the determinants of treatment success for tuberculosis cases in Europe.

作者信息

Falzon D, Le Strat Y, Belghiti F, Infuso A

机构信息

EuroTB, Institut de Veille Sanitaire, Saint-Maurice, France.

出版信息

Int J Tuberc Lung Dis. 2005 Nov;9(11):1224-9.

Abstract

SETTING

Pooled tuberculosis (TB) notifications from 13 European countries.

OBJECTIVE

To analyse the determinants of TB treatment success in different countries using individual data.

DESIGN

We asked 18 European countries with both outcome data and individual TB records to code outcomes for cases notified in 2000 and/or 2001. Cases completing treatment regardless of bacteriological proof of cure were considered successful.

RESULTS

Ten European Union countries and Iceland, Norway and Romania participated (72% response). Among 24 660 TB cases (Romania excluded), 'success' was reported in 69% (country range 60-88%), 9% (0-11%) died, 1% (0-5%) failed, 4% defaulted or transferred (2-15%) and 12% (0-23%) were 'unknown'. On logistic regression among cases with drug susceptibility results (n = 10 303), 'success' was associated with younger age (>74 years: reference; 55-74 years: OR = 2.0, 95%CI 1.8-2.4; 35-54 years: 3.0, 95%CI 2.6-3.5; 15-34 years: 3.7, 95%CI 3.2-4.4; <15 years: 4.4, 95%CI 2.9-6.7), female sex (1.4, 95%CI 1.3-1.6), and no polyresistance (9.2, 95%CI 6.8-12.4). The Netherlands (1.6, 95%CI 1.3-2.0) and Slovakia (1.8, 95%CI 1.4-2.2) had higher success than Estonia (reference: lowest percentage success), while Austria was lower (0.64, 95%CI 0.52-0.78).

CONCLUSION

Preventing drug resistance, increasing adherence and improving care in the elderly should be priorities. Inter-country variations in treatment success suggest differences in the completeness of monitoring data and in the efficacy of national control programmes.

摘要

背景

来自13个欧洲国家的结核病汇总通报。

目的

利用个体数据分析不同国家结核病治疗成功的决定因素。

设计

我们要求18个既有结局数据又有个体结核病记录的欧洲国家对2000年和/或2001年通报的病例结局进行编码。无论治疗是否有细菌学治愈证据,完成治疗的病例均视为治疗成功。

结果

10个欧盟国家以及冰岛、挪威和罗马尼亚参与了研究(回复率72%)。在24660例结核病病例(不包括罗马尼亚)中,报告“治疗成功”的比例为69%(各国范围为60%-88%),9%(0%-11%)死亡,1%(0%-5%)治疗失败,4%失访或转诊(2%-15%),12%(0%-23%)结局“不明”。在有药敏试验结果的病例(n = 10303)中进行逻辑回归分析,“治疗成功”与年龄较小有关(>74岁:参照组;55-74岁:OR = 2.0,95%CI 1.8-2.4;35-54岁:3.0,95%CI 2.6-3.5;15-34岁:3.7,95%CI 3.2-4.4;<15岁:4.4,95%CI 2.9-6.7)、女性(1.4,95%CI 1.3-1.6)以及无多重耐药(9.2,95%CI 6.8-12.4)有关。荷兰(1.6,95%CI 1.3-2.0)和斯洛伐克(1.8,95%CI 1.4-2.2)的治疗成功率高于爱沙尼亚(参照组:治疗成功率最低),而奥地利则较低(0.64,95%CI 0.52-0.78)。

结论

预防耐药、提高依从性以及改善对老年人的治疗应成为优先事项。各国治疗成功率的差异表明监测数据的完整性以及国家防控项目的效果存在差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验